By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has told Celera that its application for pre-market approval of its KIF6 Genotyping Assay is not approvable "without major amendment," Celera disclosed after the close of the market on Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.